Bridgeway Capital Management’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $333K | Sell |
114,800
-40,000
| -26% | -$116K | 0.01% | 847 |
|
|
2025
Q1 | $111K | Sell |
154,800
-30,000
| -16% | -$21.6K | ﹤0.01% | 1019 |
|
|
2024
Q4 | $190K | Hold |
184,800
| – | – | ﹤0.01% | 1022 |
|
|
2024
Q3 | $248K | Hold |
184,800
| – | – | 0.01% | 1012 |
|
|
2024
Q2 | $240K | Hold |
184,800
| – | – | 0.01% | 1014 |
|
|
2024
Q1 | $318K | Buy |
184,800
+50,000
| +37% | +$86K | 0.01% | 1026 |
|
|
2023
Q4 | $198K | Hold |
134,800
| – | – | ﹤0.01% | 1135 |
|
|
2023
Q3 | $163K | Buy |
134,800
+25,000
| +23% | +$30.3K | ﹤0.01% | 1134 |
|
|
2023
Q2 | $159K | Hold |
109,800
| – | – | ﹤0.01% | 1180 |
|
|
2023
Q1 | $159K | Buy |
+109,800
| New | +$159K | ﹤0.01% | 1144 |
|
|
2020
Q2 | – | Sell |
-69,305
| Closed | -$560K | – | 1393 |
|
|
2020
Q1 | $560K | Sell |
69,305
-1,274
| -2% | -$10.3K | 0.01% | 729 |
|
|
2019
Q4 | $679K | Buy |
70,579
+16,000
| +29% | +$154K | 0.01% | 845 |
|
|
2019
Q3 | $579K | Hold |
54,579
| – | – | 0.01% | 889 |
|
|
2019
Q2 | $628K | Hold |
54,579
| – | – | 0.01% | 901 |
|
|
2019
Q1 | $699K | Buy |
54,579
+26,000
| +91% | +$333K | 0.01% | 893 |
|
|
2018
Q4 | $176K | Sell |
28,579
-50,000
| -64% | -$308K | ﹤0.01% | 1236 |
|
|
2018
Q3 | $826K | Buy |
78,579
+23,879
| +44% | +$251K | 0.01% | 976 |
|
|
2018
Q2 | $802K | Hold |
54,700
| – | – | 0.01% | 961 |
|
|
2018
Q1 | $779K | Buy |
+54,700
| New | +$779K | 0.01% | 930 |
|